Agenda

November 12, 2018
  • 7:15 AM
    Registration and Breakfast
  • 8:15 AM
    Opening Comments from the Chair
    Kaitlyn Proulx
    Managing Director, PDCI, Market Access
    John-Paul Dowson
    Director, Reimbursement Strategy, PDCI
  • 8:30 AM
    Keynote Address
    Assess Regulatory Changes to Determine Their Impact on Your Market Access Strategy
    Matthew Kellison
    Director of Regulatory Affairs and Outreach, PMPRB

    PMPRB Framework modernization is underway with significant changes pending to both the Patented Medicine’s Regulations and PMPRB Pricing Guidelines. Gather insights on:

    • The latest developments on Health Canada’s proposal to add new factors to the PMPRB’s price ceiling setting process
    • How the PMPRB might operationalize these factors as part of its new risk-based approach to price regulation
    • What the changes will mean for pharmaceutical companies

    Discover what regulatory changes can mean to your market access strategy.

  • 9:00 AM
    Panel Discussion: PMPRB Changes
    Discuss Strategies and Perspectives on Regulatory Changes
    Lianna Paron
    Senior Manager, Market Access, Ferring Pharmaceuticals

    Changes to the Patented Medicines Regulations and PMPRB Pricing Guidelines mean the adoption of new strategies for market access professionals. After PMPRB’s keynote, discuss strategies to:

    • Develop market access strategies in accordance with regulatory changes
    • Address Health Canada’s proposal with regard to the PMPRB’s price ceilings
    • Adopt PMPRB’s new risk-based approach to price regulation

    Develop new market access strategies to adapt to regulatory changes.

  • 9:45 AM
    Innovative Medicines Canada
    Improve Access to Necessary Therapeutic Products
    Louis Theriault
    VP Policy & Research, Innovative Medicines Canada

    The Regulatory Review of Drugs and Devices (R2D2) initiative changes how you work. Review the objectives of this initiative to improve access to treatment. Stay up-to-date on:

    • Expanded collaboration with health partners
    • More timely access to drugs and devices
    • Enhanced use of real word data

    Analyse the R2D2 initiative to enhance access to treatment.

  • 10:15 AM
    Mid-morning Networking Break
  • 10:45 AM
    Industry Expert Panel Discussion: RWE
    Adopt Innovative Solutions in the Use of Real-world Evidence to Enhance your Decision-making

    Governments, payers and healthcare’s other stakeholders increasingly look to incorporate data to support decision-making. Explore innovation in Real-World Evidence to improve the value, efficacy and impact of medicines. Take away strategies to:

    • Enhance efficacy of your medicines on individual patient outcomes
    • Evaluate the impact on the health of the overall populations
    • Partner with your stakeholders to access data

    Prove and improve the value, efficacy and impact of your medicines with RWE.

  • 11:30 AM
    Alberta
    Assessing Drug and Therapeutics Committee Processes, the Need for a Tangible System of Benefits and How Alberta Looks at Outcomes
    Jeremy Slobodan
    Director, Drug Utilization, Information & Stewardship, Alberta Health Services

    Regional health authorities are working to improve alignment with public drug plans and utilize the best available evidence when reviewing hospital only drugs. Clarify how Alberta approaches DTC processes, what information about system costs AHS uses to make decisions and evaluate some of the work that has been done to date to improve your market access strategy. Gain insights to:

    • Align with the Alberta Drug Benefit List
    • Improve Market Access around DTC Processes
    • Understand how RFPs are done

    Evaluate the evolution of decision-making at the regional level and its effects on your organization.

  • 12:15 PM
    Networking Lunch
  • 1:15 PM
    Panel Discussion: Patient Advocacy
    Provide Patient Access to the Right Treatment at the Right Time
    Laura Tamblyn Watts
    National Director, Law, Policy & Research, CARP
    Robyn Widenmaier
    Scientific Advisor, GSK
    Gregory R. Shaw
    Director, International and Corporate Relations, International Federation on Ageing

    Reconciling the urgency of patient need with a thorough HTA process is a growing a challenge. Explore what patients expect from you to improve patient outcomes. Gain insights to:

    • What patient centricity means to the end user (the patient)
    • Refine your stakeholder mapping
    • Advance your stakeholder engagement process

    Ensure the patients are at the centre of your strategic planning.

  • 2:00 PM
    Industry Expert Panel Discussion: Patient Support
    Predictive Analytics in Patient Support – Fact or Fiction?
    TBD
    Senior Executive, STI

    There is a lot of buzz around harnessing historic trends and patterns in patient data - is it hype or reality? Many wonder if it will impact PSP design and implementation and whether patients will benefit. Take away a plan to understand:

    • What is predictive analytics in the PSP environment?
    • Is it actionable?
    • What is the impact on patient engagement?
    • Can informed analytics impact patient outcomes?

    Understand how predictive analytics in patient support could help your organization.

  • 2:45 PM
    Quebec Update
    Understand How Provincial Changes Impact your Market Access Strategy
    Sylvie Bouchard
    Director of Medication, Institut National d'Excellence en Sante et en Services Sociaux (INESSS)

    Complying with Provincial expectations for product listing agreements is critical to your market access strategy. Ensure you meet the needs of key provinces to get your product to market. Gain practical tips to:

    • Get your product to market faster
    • Clarify upcoming changes to PLAs
    • Review your value proposition

    Gain practical insights on how to list your drug with a province.

  • 3:15 PM
    Mid-afternoon Networking Break
  • 3:45 PM
    Panel Discussion: Private Payers
    Analyze Emerging Trends Among Private Payers and Adapt to Change
    Suzanne Lepage
    Private Health Plan Strategist, Suzanne Lepage Consulting
    Barbara A. Martinez
    National Practice Leader, Drug Benefits Solutions, Great West Life
    Noel MacKay
    Director, Benefits Consulting, Cowan Insurance Group

    The private payer landscape is undergoing significant changes that will impact patient access and how medications are reimbursed. Strengthen your market access strategy with insights into emerging trends in the private payer landscape. Source critical information to:

    • Assess trends among large employers
    • Revise changes in industry leadership and emerging partnerships
    • Review the solutions plan sponsors are considering

    Integrate the employer’s outlook into your market access strategies.

  • 4:30 PM
    Case Study: Orphan Drugs
    Collaborate with Stakeholders to Develop your Products and Improve Patient Outcomes
    Durhane Wong-Rieger
    President & CEO, CORD

    Small markets can impede the development of orphan drugs, but collaboration can alleviate some restraints. Build partnerships to develop your new products and secure revenue opportunities. Build a roadmap to:

    • Explore funding and joint research opportunities
    • Gather inputs from patients
    • Optimize your company’s ROI in a small market

    Work with your stakeholders to increase patient access to treatments.

  • 5:00 PM
    Conference Adjourns to Day Two
  • 5:05 PM
    Evening Executive Reception
November 12, 2018
November 13, 2018
  • 7:15 AM
    Registration and Breakfast
  • 8:15 AM
    Opening Comments from the Chair
  • 8:30 AM
    Keynote Address
    Evaluate CADTH’s Priority to Minimize Delays in your Submissions
    Brent Fraser
    Vice-President of Pharmaceutical Reviews, CADTH

    CADTH CDR made changes to improve transparency and HTA timelines. Explore what these changes can do to streamline your submissions. Source intelligence on:

    • New advanced notifications for expedited Health Canada Review
    • Closer partnerships between CDR and pCPA
    • Changes in the 4th HTA guidelines

    Align with new CDR guidelines to advance your approval processes.

  • 9:00 AM
    International Pricing
    Pricing Trends: International Listing and Pricing Frameworks
    Paul Catchpole
    Value & Access Director, Association of the British Pharmaceutical Industry

    The most extensive changes to medicines policy for the last five years are being introduced in the UK:

    • New medicines pricing and policy scheme
    • Evolution of the UK market access environment and architecture, including use of real world evidence in HTA
    • Shared challenges across Canada and the UK
    • Solutions in multi-indication pricing, combination pricing and ATMPs

    Unleash the full potential of market access solutions for your company by taking a page out of international playbooks.

  • 9:30 AM
    Industry Expert: Data
    Utilize Data Insights to Improve Your Company’s Drug Plan Design
    TBA
    TBA, Telus Health

    Plan designs impact drug utilization by influencing patient behaviour. Identify new trends in plan design and their impact on your market access strategy. Discover insights to:

    • Enrich your forecasting on patient assistance programs
    • Optimize the linkage between plan design and drug plan data
    • Implement strategies to manage drug plan costs

    Utilize experienced perspectives on data integration to bolster your company’s access strategies

  • 10:00 AM
    Mid-morning Networking Break
  • 10:30 AM
    Panel Discussion: PDCI
    TBA
  • 11:30 AM
    Panel Discussion: Companion Diagnostic Tests
    Anticipate a Need to Include Relevant Companion Diagnostics Tests with Your New Drug Submissions
    Christopher Trevors
    National Director - Genetic Health Solutions, Dynacare

    CDR guidelines are likely to change and major lab diagnostic testing companies and patient support programs are pro-acting for this eventuality. Adapt to changing CDR guidelines and Improve your submissions with companion diagnostic tests. Source intelligence to:

    • Highlight changes to CDR
    • Discuss commercialization of companion diagnostics
    • Review how payers intend to integrate these requirements into their coverage plans

    Strengthen your new submission with relevant companion diagnostic tests.

  • 12:15 PM
    Networking Lunch
  • 1:15 PM
    pCPA Update
    Review pCPA Approach to Negotiation and Pricing to Prepare your Submissions Better
    Imran Ali
    Senior Manager, pan-Canadian Pharmaceutical Alliance

    The pCPA changed notably in the past few years and its approach to negotiation has evolved. Reassess your expectation and improve your submissions. Source Intelligence to:

    • Enhance the use of your company’s research and marketing resources
    • Facilitate communication between your company, the federal government and the provinces

    Review changes at pCPA to enhance your submission process.

  • 1:45 PM
    Payer Partnerships
    Optimize your Access When Negotiating With Group Purchasing Organizations
    Rosemarie Childerhose
    Lead, Patient Relations and Government Relations, Bausch Health

    The growing transparency at CADTH and shrinking hospital budgets are changing the perspective of GPOs. Adapt to GPO’s approach to ensure your access to hospital and community care. Create a roadmap to:

    • Analyze the work of hospital review boards within GPOs
    • Clarify purchase criteria
    • Address cost concerns

    Work with your stakeholders to increase patient access to treatments.

  • 2:15 PM
    Mid-afternoon Networking Break
  • 2:45 PM
    Industry Expert Panel Discussion: Biosimilars
    Biosimilar Reimbursement Pathways in the Oncology Therapeutic Space
    Ross Wallace
    Principal, Santis Health
    Sang Mi Lee
    Senior Pharmacist, pCPA
    Erika Brown
    Executive Director, Canadian Association of Provincial Cancer Agencies

    The next wave of biosimilars is entering the Canadian market and present unique considerations not part of the current landscape. Avoid silos and discover how to develop an interconnected policy approach with different pan-Canadian system leaders and payer organizations. Learn about the considerations associated with institutionally-based products such as oncology therapeutic biosimilars, including:

    • Pharmaceutical policy related to reimbursement
    • Regulatory review, naming convention, health technology assessment, and public funding
    • Key differences related to levels of evidence, funding mechanisms and patient advocacy

    Assess how the market and policies are evolving as the first Oncology therapeutic biosimilars pass through the reimbursement system.

  • 3:45 PM
    Patient Support Programs
    Advance Patient’s Access to your Medication by Leveraging Patient Support Programs
    Suzanne Lepage
    Private Health Plan Strategist, Suzanne Lepage Consulting
    Ian McQueen
    Partner, Matrix Healthcare

    As private coverage becomes increasingly complex, Patient Support Programs (PSPs) are a valuable tool to assist patients’ access to your medications. Optimize your programs to ensure they are aligned and integrated with private payer programs to maximize patient access. Gain insights to:

    • How PSPs generate valuable private payer data that offers important insights
    • How private payer teams are collaborating with their PSP colleagues to leverage PSP data

    Leverage PSPs to improve your private payer programs.

  • 4:30 PM
    Conference Adjourns
November 13, 2018
November 14, 2018
  • 9:00 AM - 12:00 PM
    Post-Conference Workshop: Product Listing Agreement
    Drive Successful pCPA Strategies and PLAs to Solidify your Market Access Strategies
    Colin Vicente
    Managing Director, Pivina

    The pan-Canadian Pharmaceutical Alliance (pCPA) has established their office and become a formal process for getting new drugs to the market. Source insights to manage and optimize your submission. Tap into both public and private perspectives in this interactive workshop and walk away with knowledge to:

    1. Understand the pCPA process and submissions
    2. Prepare for pCPA in the planning stages of your products
    3. Use pricing models to assist your product’s positioning during negotiations
    4. Gain an understanding of different types of Canadian PLAs
    5. Take advantage of potential opportunities in private sector PLAs

    Develop your successful pCPA strategy through this hands-on interactive workshop.

November 14, 2018

Download Brochure - Gain new ideas and practical strategies for implementation

  • This field is for validation purposes and should be left unchanged.